Biospecimen Collection (NCT06770582)

Name: Biospecimen Collection trial for Non-Muscle Invasive Bladder Urothelial Carcinoma (NCT06770582)
Uploaded: 2026-10-31T22:13:41.476Z
Duration: 1 min 25 s
Description: Biospecimen Collection trial for Non-Muscle Invasive Bladder Urothelial Carcinoma (NCT06770582). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06770582.

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial: a one-minute explainerNCT067705821 min

Biospecimen Collection trial for Non-Muscle Invasive Bladder Urothelial Carcinoma (NCT06770582). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with high-grade T1 bladder cancer without nodal or distant spread, with bladder removal recommended. Disease must recur after bladder-instilled treatment, persist after repeat resection, or have specified high-risk features.

The idea: compare pembrolizumab plus radiation with chemotherapy plus radiation. Pembrolizumab blocks PD-1 immune suppression and is infused every six weeks for nine cycles. The chemotherapy group receives cisplatin, gemcitabine, or mitomycin with fluorouracil. Researchers measure bladder-intact event-free survival.

This phase 2 study plans 160 patients. Brian Baumann leads the NCI-sponsored study across 142 recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.